Patents by Inventor Robert W. Malone

Robert W. Malone has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11416616
    Abstract: A system is provided for managing booting of an OS that includes a UEFI controller comprising embedded application code instructions and a pre-loaded signed certificate, a boot process controller comprising application code instructions for the OS, pre-loaded signed certificates, and a plurality of application hash identifiers. The boot process controller receives signed communications from the UEFI controller and determines if the UEFI controller is authorized to manage the OS. The UEFI controller manages the OS in response to a positive authorization. The boot process controller determines if the UEFI controller is authorized to manage the OS in response to installation or execution of the OS. The UEFI controller receives a signed communication from the boot loader program, compares the signed communications with the plurality of application identifiers, and executes the boot loader program in response to the pre-loaded signed certificate matching an application identifier from the plurality.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: August 16, 2022
    Assignee: FORCEPOINT LLC
    Inventors: Robert W. Kliewer, Micky S. Martin, Mickey J. Malone, II
  • Publication number: 20040009947
    Abstract: The discovery of simple, nontoxic, and pharmaceutically defined methods for genetic modification of cells and tissues would enable development of a variety of molecular medicines. “Free”, ‘direct’, or ‘naked’ polynucleotide administration is a simple, apparently safe, and pharmaceutically defined polynucleotide delivery method. Murine, macaque, and clinical human experiments have demonstrated transfection of various tissues, such as respiratory tissues, after direct application of ‘free’ polynucleotide. However, direct DNA transfection is relatively inefficient in comparison to many transduction systems. The invention herein is directed to transfection enhancing agents which augment the transfection activity of ‘free’ polynucleotide, thereby facilitating the development of simple and safe alternatives to tissue transfection, more particularly respiratory tissue transfection.
    Type: Application
    Filed: May 27, 2003
    Publication date: January 15, 2004
    Inventors: Robert W. Malone, Jill G. Malone
  • Patent number: 6110898
    Abstract: The invention consists of a method for inducing production of a mucosal immune response in a host by administration of an antigen-encoding polynucleotide preparation, comprising DNA or RNA encoding an antigenic epitope to a mucosal inductor site in the mucosal tissue of the host. Naked DNA may be administered directly to mucosa, for instance in saline drops, or in a recombinant gene expression vector. Preferably, the recombinant gene expression vectors are not capable of replication or dessimination. The invention also includes the use of live viral vaccines wherein the viruses include immunostimulatory polynucleotides of the invention. According to a preferred method of the invention, a target protein antigen is administered through its expression by a recombinant gene expression vector.
    Type: Grant
    Filed: May 23, 1997
    Date of Patent: August 29, 2000
    Assignee: University of Maryland, Baltimore
    Inventors: Robert W. Malone, Jill G. Malone
  • Patent number: 5925623
    Abstract: In the generation of cytofectin:polynucleotide complexes for transfection of cells, formulations, counterions, and reaction conditions for maximizing the transfection include using a cationic amine compound that has the general structure: ##STR1## wherein R.sub.4 and R.sub.5 are a pair of same or different lipoyl moieties selected from a group consisting of an alkyl, alkenyl, alkynyl, alkanoyl, alkenoyl, or alkynoyl groups and for R.sub.1, R.sub.2, and R.sub.3 at least two are hydroxylated, ether containing, or acyloxy containing alkyl, alkenyl, or alkynyl groups or at least one amine bonded halogen containing moiety selected from a group consisting of a halogenated alkyl, alkenyl, or alkynyl group or a mixture of at least one halogen containing moiety selected from a group consisting of a halogenated alkyl, alkenyl, or alkynyl group and at least one hydroxylated, ether containing, or acyloxy containing alkyl, alkenyl, or alkynyl group, and X.sup.- is an oxyanion or halide counterion.
    Type: Grant
    Filed: July 15, 1996
    Date of Patent: July 20, 1999
    Assignee: The Regents of the University of California
    Inventors: Michael H. Nantz, Michael J. Bennett, Rajiv P. Balasubramaniam, Alfred M. Aberle, Robert W. Malone
  • Patent number: 5892071
    Abstract: For use in transporting biologically active species into and through membrane barriers, a symmetrical cationic diamine compound having the general structure ##STR1## wherein m=1-10; R.sub.1 is a hydrogen, an alkyl group, an alkenyl group, a hydroxylated alkyl or alkenyl group, or an ether containing alkyl or alkenyl group; R.sub.2 is an alkyl group, an alkenyl group, or an alkyl or alkenyl containing acyl group; R.sub.3 is a hydrogen, an alkyl group, an alkenyl group, a hydroxylated alkyl or alkenyl group, or an ether containing alkyl or alkenyl group; R.sub.4 is a hydrogen, an alkyl group, an alkenyl group, a hydroxylated alkyl or alkenyl group, or an ether containing alkyl or alkenyl group; and X.sup.- is an anion.
    Type: Grant
    Filed: September 15, 1995
    Date of Patent: April 6, 1999
    Assignee: The Reagents of The University of California
    Inventors: Michael H. Nantz, Michael J. Bennett, Robert W. Malone
  • Patent number: 5824812
    Abstract: Amine containing compounds and their use in the generation of cytofectin:polynucleotide complexes for transfection of cells, formulations, counterions, and reaction conditions for maximizing the transfection include using cationic amine compounds that have the general structure: ##STR1## wherein R.sub.4 and R.sub.5 are a pair of same or different lipoyl moieties selected from a group consisting of an alkyl, alkenyl, alkynyl, alkanoyl, alkenoyl, or alkynoyl groups and for R.sub.1, R.sub.2, and R.sub.3 at least two are hydroxylated, ether containing, or acyloxy containing alkyl, alkenyl, or alkynyl groups or at least one amine bonded halogen containing moiety selected from a group consisting of a halogenated alkyl, alkenyl, or alkynyl group or a mixture of at least one halogen containing moiety selected from a group consisting of a halogenated alkyl, alkenyl, or alkynyl group and at least one hydroxylated, ether containing, or acyloxy containing alkyl, alkenyl, or alkynyl group, and X.sup.
    Type: Grant
    Filed: September 17, 1996
    Date of Patent: October 20, 1998
    Assignee: The Regents of the University of California
    Inventors: Michael H. Nantz, Michael J. Bennett, Rajiv P. Balasubramaniam, Alfred M. Aberle, Robert W. Malone
  • Patent number: 5744625
    Abstract: For use transporting biologically active species into and through membrane barriers, a symmetrical cationic diamine compound having the general structure ##STR1##
    Type: Grant
    Filed: May 16, 1996
    Date of Patent: April 28, 1998
    Assignee: The Reagents of the University of California
    Inventors: Michael H. Nantz, Michael J. Bennett, Robert W. Malone
  • Patent number: 5589466
    Abstract: A method for delivering an isolated polynucleotide such as DNA or RNA, to the interior of a cell in a mammal comprising the injection of an isolated polynucleotide into a muscle of the mammal where the polynucleotide is taken up by the cells of the muscle and exerts a therapeutic effect on the mammal. The method can be used to deliver a therapeutic polypeptide to the cells of the mammal, to provide an immune response upon in vivo translation of the polynucleotide, to deliver antisense polynucleotides, to deliver receptors to the cells of the mammal or to provide transitory gene therapy.
    Type: Grant
    Filed: January 26, 1995
    Date of Patent: December 31, 1996
    Assignees: Vical Incorporated, Wisconsin Alumni Research Foundation
    Inventors: Philip L. Felgner, Jon A. Wolff, Gary H. Rhodes, Robert W. Malone, Dennis A. Carson
  • Patent number: 5580859
    Abstract: Polynucleotide sequences, comprising DNA and RNA molecules can be directly administered, for example by injection, to tissues, such as muscle, and expressed as a protein, polypeptide or polypeptide. The polynucleotides can be contained within liposomes or the polynucleotides can free from association with transfection-facilitating proteins, viral particles, liposomal formulations, charged lipids and calcium phosphate precipitating agents.
    Type: Grant
    Filed: March 18, 1994
    Date of Patent: December 3, 1996
    Assignees: VICAL Incorporated, Wisconsin Alumni Research Foundation
    Inventors: Philip L. Felgner, Jon A. Wolff, Gary H. Rhodes, Robert W. Malone, Dennis A. Carson
  • Patent number: 5527928
    Abstract: For use in transporting biologically active species into and through membrane barriers, a symmetrical cationic diamine compound having the general structure ##STR1##
    Type: Grant
    Filed: September 30, 1994
    Date of Patent: June 18, 1996
    Inventors: Michael H. Nantz, Michael J. Bennett, Robert W. Malone